Recent investor news
Biogen Idec is a Fortune 500 company and global biotechnology leader that generates more than $6.9 billion in annual revenues. Our mission is to discover, develop and deliver innovative therapies for the treatment of neurodegenerative diseases, hemophilia, and immunology to patients worldwide through cutting-edge science and medicine. Our robust product pipeline is supported by one of the industry’s leading capacities for biologics manufacturing, featuring nearly 200,000 liters of bioreactor capacity.
We have approximately 7,000 employees worldwide and a direct commercial presence in more than 30 markets and a network of distribution partners in more than 50 additional markets, including emerging markets such as Central and Eastern Europe, Brazil, Japan and India. We pursue our mission through a strategic combination of internal research and development and through partnerships, alliances, and acquisitions.
With an unshakeable commitment to our mission and values, we expect to build shareholder value by bringing meaningful therapies to patients with serious, unmet medical needs.
Receive E-mail Alerts
Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.